Arysta Lifescience signs license agreement with IPP

New research models for studying crops
New research models for studying crops | Courtesy of

Arysta LifeScience now has exclusive global access (excluding China) to protein technologies of the Institute of Plant Protection (IPP), thanks to a licensing agreement the two companies recently signed. 

Arysta LifeScience has access to the protein technologies as well as all related end-use formulations and the right to develop new formulations and mixtures.

IPP is part of the Chinese Academy of Agricultural Science (CAAS) and has been developing a platform for over a decade. The platform includes selecting, identifying, qualifying and patenting plant immunity inducers from fungal pathogens.

PeaT1 is a protein from Altermaria tenuissima, which was derived from the technologies developed from the platform from IPP. It was formulated by IPP in June 2014 into an end-use product registered in China with Institute for the Control of Agrochemicals, Ministry of Agriculture (ICAMA). It was launched under the brand Atailing as the first plant immunoprotein biopesticide for control of viral diseases in vegetables and tobacco. Another protein derived from the same pathogen that is also under the licensing rights is called Hrip1; Arysta and IPP hope it will be successful as a commercial biopesticide.

"These technologies are unique in the industry and represent an innovative and effective approach toward disease control in agricultural crops, such as citrus, tobacco and a number of vegetables," said Paula Pinto, global head of portfolio management of Arysta LifeScience. "This agreement complements our growing portfolio of biosolutions products and will allow us to further expand our offerings to growers around the world."

Organizations in this Story

Arysta LifeScience

Want to get notified whenever we write about Arysta LifeScience ?
Next time we write about Arysta LifeScience, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.